AU2020282791A1 - Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor - Google Patents

Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor Download PDF

Info

Publication number
AU2020282791A1
AU2020282791A1 AU2020282791A AU2020282791A AU2020282791A1 AU 2020282791 A1 AU2020282791 A1 AU 2020282791A1 AU 2020282791 A AU2020282791 A AU 2020282791A AU 2020282791 A AU2020282791 A AU 2020282791A AU 2020282791 A1 AU2020282791 A1 AU 2020282791A1
Authority
AU
Australia
Prior art keywords
domain variant
sirpa
individual
domain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020282791A
Other languages
English (en)
Inventor
Jaume Pons
Sophia Randolph
Hong Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALX Oncology Inc
Original Assignee
ALX Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALX Oncology Inc filed Critical ALX Oncology Inc
Publication of AU2020282791A1 publication Critical patent/AU2020282791A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020282791A 2019-05-31 2020-05-28 Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor Pending AU2020282791A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855821P 2019-05-31 2019-05-31
US62/855,821 2019-05-31
US202063022187P 2020-05-08 2020-05-08
US63/022,187 2020-05-08
PCT/US2020/034966 WO2020243338A1 (en) 2019-05-31 2020-05-28 Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
AU2020282791A1 true AU2020282791A1 (en) 2021-12-09

Family

ID=71787033

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020282791A Pending AU2020282791A1 (en) 2019-05-31 2020-05-28 Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor

Country Status (16)

Country Link
US (5) US11613564B2 (https=)
EP (1) EP3976099A1 (https=)
JP (2) JP7710997B2 (https=)
KR (1) KR20220044904A (https=)
CN (3) CN119700933A (https=)
AU (1) AU2020282791A1 (https=)
BR (1) BR112021024003A2 (https=)
CA (1) CA3141130A1 (https=)
CL (1) CL2021003174A1 (https=)
CO (1) CO2021017299A2 (https=)
IL (1) IL288390A (https=)
MA (1) MA56045A (https=)
MX (1) MX2021014627A (https=)
SG (1) SG11202112733XA (https=)
WO (1) WO2020243338A1 (https=)
ZA (1) ZA202109198B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
US12343377B2 (en) 2020-06-01 2025-07-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
CN117255690A (zh) 2021-05-03 2023-12-19 塞尔美迪有限公司 用于预防或治疗肺癌的药物组合物
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2023218378A1 (en) * 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2026051964A1 (en) * 2024-09-04 2026-03-12 Akeso Biopharma Co., Ltd. Antibody that binds vegfa and pd-1 and uses thereof to treat cancers

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
FI101678B1 (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH11510050A (ja) 1995-07-25 1999-09-07 イントロヘーネ ベスローテン フェンノートシャップ 標的遺伝子送達のための方法および手段
WO1997029701A1 (en) 1996-02-15 1997-08-21 Biosense Inc. Catheter based surgery
EP0920339A2 (en) 1996-07-09 1999-06-09 The Johns Hopkins University Gene delivery system
US6541615B1 (en) 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
JP2003502062A (ja) 1999-06-11 2003-01-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
US6613026B1 (en) 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20040018522A1 (en) 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
WO2004011618A2 (en) 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
WO2004024097A2 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
MXPA06009805A (es) 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
EP1737480A2 (de) 2004-03-29 2007-01-03 Seth Hallström Pharmazeutisches kombinationspr parat enthaltend ein therape utisches protein
WO2005108415A2 (en) 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
BRPI0810561A2 (pt) 2007-04-23 2019-09-24 Wyeth Corp métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US20100239578A1 (en) 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US20110237498A1 (en) 2008-12-19 2011-09-29 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
PL2995315T3 (pl) 2009-05-15 2024-04-22 University Health Network Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47
US20110015130A1 (en) 2009-07-20 2011-01-20 Woei-Jer Chuang Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
ES2751549T3 (es) 2009-11-30 2020-04-01 Janssen Biotech Inc Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
CN103501815B (zh) 2010-10-08 2016-09-28 希望之城公司 针对中间位的单克隆抗体框架结合界面、中间位投递系统及其使用方法
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
WO2012109267A2 (en) 2011-02-07 2012-08-16 The Trustees Of The University Of Pennsylvania Novel peptides and methods using same
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
UA118950C2 (uk) 2011-04-22 2019-04-10 Аптево Рісьорч Енд Девелопмент Ллс Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
MX2013014789A (es) 2011-06-16 2014-01-20 Novartis Ag Proteinas solubles para utilizarse como productos terapeuticos.
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013063076A1 (en) 2011-10-25 2013-05-02 Indiana University Research & Technology Corporation Compositions for and methods of modulating complications, risks and issues with xenotransplantation
SI2804617T1 (sl) 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
MX2014016038A (es) 2012-06-22 2015-08-14 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
GB201216649D0 (en) 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
ES2914814T3 (es) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
CA2900256C (en) 2013-02-05 2023-03-21 Kim J. HASENKRUG Cd47 targeted therapies for the treatment of infectious disease
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
PT2970493T (pt) 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
ES2898627T3 (es) 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
WO2014186761A2 (en) 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
SG11201600734YA (en) 2013-07-31 2016-02-26 Amgen Inc Stabilization of fc-containing polypeptides
ES2765483T3 (es) 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
CN105592695B (zh) 2013-09-23 2018-04-10 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10087257B2 (en) 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
TWI759810B (zh) 2014-08-08 2022-04-01 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
US9546206B2 (en) 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
HUE046661T2 (hu) 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
FI3656869T4 (fi) 2014-08-26 2025-06-04 Univ Leland Stanford Junior Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
EP3194024B1 (en) 2014-09-15 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
WO2016057980A1 (en) 2014-10-10 2016-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting cd47
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
PT3212670T (pt) * 2014-10-29 2021-02-15 Bristol Myers Squibb Co Terapêutica de combinação para cancro
CA2967379A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
US11253588B2 (en) 2015-02-27 2022-02-22 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for treatment of coronary artery disease
CN106146670B (zh) 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
US10613092B2 (en) * 2016-04-01 2020-04-07 Agilent Technologies, Inc. Scoring methods for anti-PD therapy eligibility and compositions for performing same
SG11201808465UA (en) 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
FR3053561A1 (fr) 2016-06-29 2018-01-05 Orange Controle de connexion a un reseau local installe a bord d'un vehicule
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2017339517B2 (en) * 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
PT3565844T (pt) * 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
JP2020515637A (ja) * 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
AU2019218271B2 (en) * 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
US12343377B2 (en) * 2020-06-01 2025-07-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
JP2024520902A (ja) * 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法

Also Published As

Publication number Publication date
CO2021017299A2 (es) 2022-01-17
US20200392199A1 (en) 2020-12-17
JP2025003971A (ja) 2025-01-14
US20240132567A1 (en) 2024-04-25
KR20220044904A (ko) 2022-04-12
CN114126648A (zh) 2022-03-01
WO2020243338A1 (en) 2020-12-03
MX2021014627A (es) 2022-01-06
SG11202112733XA (en) 2021-12-30
BR112021024003A2 (pt) 2022-04-19
JP7710997B2 (ja) 2025-07-22
JP2022534212A (ja) 2022-07-28
ZA202109198B (en) 2025-04-30
EP3976099A1 (en) 2022-04-06
US20240228574A9 (en) 2024-07-11
CN119700932A (zh) 2025-03-28
US20220242928A1 (en) 2022-08-04
CL2021003174A1 (es) 2022-07-22
IL288390A (en) 2022-01-01
US20220213166A1 (en) 2022-07-07
US11613564B2 (en) 2023-03-28
CN119700933A (zh) 2025-03-28
CA3141130A1 (en) 2020-12-03
US20250368712A1 (en) 2025-12-04
MA56045A (fr) 2022-04-06

Similar Documents

Publication Publication Date Title
US20220213166A1 (en) Methods of treating cancer
US12527838B2 (en) Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel
US20160369012A1 (en) Hybrid constant regions
CA2879814A1 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
US12098214B2 (en) Combination therapies for treating cancer
US20240010701A1 (en) Combination therapies for treating urothelial carcinoma
JP2025500918A (ja) Ｔｎｆｓｆリガンドの細胞外ドメインを含有する抗原結合ポリペプチド複合体
CN117279633A (zh) 用于治疗癌症的组合疗法